We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




The Grapefruit Flavonoid Naringenin Modulates Fatty Acid Metabolism in the Liver

By LabMedica International staff writers
Posted on 09 Sep 2010
Print article
The mechanism by which the grapefruit flavonoid naringenin regulates fatty acid metabolism at the molecular level is directly related to its effect on a group of nuclear receptors including PPAR-alpha (peroxisome proliferator-activated receptor alpha), PPAR-gamma (peroxisome proliferator-activated receptor gamma), and LXR-alpha (liver X receptor alpha).

Naringenin is a flavonoid that has been shown in previous research to have a bioactive effect on human health as an antioxidant, a free radical scavenger, an anti-inflammatory, a carbohydrate metabolism promoter, and an immune system modulator. This substance has also been shown to reduce oxidative damage to DNA in vitro. It is the predominant flavanone in grapefruit.

Naringenin has also been shown to reduce hepatitis C virus production by infected hepatocytes in cell culture. This effect seems to be linked to naringenin's ability to inhibit the secretion of very-low-density lipoprotein by the cells. In this regard, naringenin seems to protect LDLR-deficient mice from the obesity effects of a high-fat diet. It lowers plasma and hepatic cholesterol concentrations by suppressing HMG-CoA reductase and ACAT in rats fed a high-cholesterol diet.

In the current study, investigators at the Hebrew University of Jerusalem (Israel) and Massachusetts General Hospital (Boston, USA) studied the effect of naringenin on cultures of rat and human liver cells. They reported in the August 25, 2010, online edition of the journal PLoS ONE that naringenin regulated the activity of nuclear receptors PPAR-alpha, PPAR-gamma, and LXR-alpha. It activated the ligand-binding domain of both PPAR-alpha and PPAR-gamma, while inhibiting LXR-alpha in GAL4-fusion reporters. This effect resulted in the induction of a fasted-like state in primary rat hepatocytes in which fatty acid oxidation increased, while cholesterol and bile acid production decreased. The induction of PPAR-alpha and inhibition of LXR-alpha induced transcriptional changes in hepatocytes, upregulating genes important in fatty acid oxidation and down-regulating cholesterol and fatty acid synthesis.

"It is a fascinating find," said senior author Dr. Yaakov Nahmias, professor of engineering at the Hebrew University of Jerusalem. "We show the mechanism by which naringenin increases two important pharmaceutical targets, PPAR-alpha and PPAR-gamma, while blocking a third, LXR-alpha. The results are similar to those induced by long periods of fasting. Dual PPAR-alpha and PPAR-gamma agonists, like naringenin, were long sought after by the pharmaceutical industry, but their development was plagued by safety concerns. Remarkably, naringenin is a dietary supplement with a clear safety record. Evidence suggests it might actually protect the liver from damage."

Related Links:
Hebrew University of Jerusalem
Massachusetts General Hospital


Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Ultra-Low Temperature Freezer
iUF118-GX
New
FOB+Transferrin+Calprotectin+Lactoferrin Test
CerTest FOB+Transferrin+Calprotectin+Lactoferrin Combo Test

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: The advanced molecular test is designed to improve diagnosis of a genetic form of COPD (Photo courtesy of National Jewish Health)

Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD

Chronic obstructive pulmonary disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD) are both conditions that can cause breathing difficulties, but they differ in their origins and inheritance.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.